Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation by Pan, Min-Hsiung et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 562187, 12 pages
doi:10.1093/ecam/nep093
Original Article
Suppression of Heregulin-β1/HER2-Modulated Invasive and
A ggr essi v eP he notypeo fB r ea stC a r cino mab yPt e r ostilbe nevia
Inhibitionof Matrix Metalloproteinase-9, p38 KinaseCascade
andAktActivation
Min-HsiungPan,1 Ying-TingLin,2 Chih-LiLin,3 Chi-ShiangWei,2 Chi-Tang Ho,4
and Wei-Jen Chen2
1Department of Seafood Science, National Kaohsiung Marine University, Nan-Tzu, Kaohsiung, Taiwan
2Department of Biomedical Sciences, Chung Shan Medical University, No. 110, Section 1, Chien-Kuo N. Road, Taichung 402, Taiwan
3Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
4Department of Food Science, Cook College, Rutgers University, New Brunswick, NJ, USA
Correspondence should be addressed to Wei-Jen Chen, cwj519@csmu.edu.tw
Received 26 April 2009; Accepted 25 June 2009
Copyright © 2011 Min-Hsiung Pan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Invasive breast cancer is the major cause of death among females and its incidence is closely linked to HER2 (human epidermal
growth factor receptor 2) overexpression. Pterostilbene, a natural analog of resveratrol, exerts its cancer chemopreventive
activity similar to resveratrol by inhibiting cancer cell proliferation and inducing apoptosis. However, the anti-invasive eﬀect
of pterostilbene on HER2-bearing breast cancer has not been evaluated. Here, we used heregulin-β1( H R G - β1), a ligand for
HER3, to transactivate HER2 signaling. We found that pterostilbene was able to suppress HRG-β1-mediated cell invasion, motility
and cell transformation of MCF-7 human breast carcinoma through down-regulation of matrix metalloproteinase-9 (MMP-9)
activity and growth inhibition. In parallel, pterostilbene also inhibited protein and mRNA expression of MMP-9 driven by HRG-
β1, suggesting that pterostilbene decreased HRG-β1-mediated MMP-9 induction via transcriptional regulation. Examining the
signaling pathways responsible for HRG-β1-associated MMP-9 induction and growth inhibition, we observed that pterostilbene,
as well as SB203580 (p38 kinase inhibitor), can abolish the phosphorylation of p38 mitogen-activated protein kinase (p38 kinase),
a downstream HRG-β1-responsive kinase responsible for MMP-9 induction. In addition, HRG-β1-driven Akt phosphorylation
required for cell proliferation was also suppressed by pterostilbene. Taken together, our present results suggest that pterostilbene
may serve as a chemopreventive agent to inhibit HRG-β1/HER2-mediated aggressive and invasive phenotype of breast carcinoma
through down-regulation of MMP-9, p38 kinase and Akt activation.
1.Introduction
Invasive breast cancer is the most frequent cause of death
among women in the industrialized world [1] and its
incidence tightly correlates with genetic abnormalities such
as HER2 (human epidermal growth factor receptor 2).
Numerous studies have shown that HER2-positive breast
cancer is highly proliferative and invasive with metastatic
potential [2–5]. A literature reviewing 81 studies and 27 161
patients with respect to HER2 reveals that ampliﬁcation or
overexpression of HER2 is closely linked to axillary-lymph-
node metastases with poor outcome, which protrudes the
prognostic value of HER2 in evaluating the development of
invasive breast carcinoma [6].
Molecular mechanisms by which HER2 deregulation
promotes cell invasion and metastasis of breast carci-
noma are less known yet. However, several investiga-
tions have provided information on the biology of breast
cancer dissemination in response to HER2 hyperactiva-
tion. Reduction of HER2 activity or expression leads to
down-regulation of Akt and ERK1/2 signaling and, con-
sequently, represses the expression of angiopoietin-2, an
initial factor required for tumor angiogenesis, indicating
that HER2 mediates tumor angiogenesis and metastasis by2 Evidence-Based Complementary and Alternative Medicine
up-regulation of angiopoietin-2 expression [7]. In HER2-
overexpressing cells, transforming growth factor-β activates
phosphotidylinositol 3-kinase (PI3K), and then recruits and
stabilizes actin/actinin/HER2 complex at cell protrusions,
which sustains prolonged Rac1 activation, and enhances
cell motility and invasiveness [8]. HER2 activity may assist
breast cancer cells in homing to speciﬁc metastatic organs
via enhancement of chemokine receptor CXCR4 expression
or stability [9]. Using phosphor-speciﬁc antibodies against
c-Src and focal adhesion kinase (FAK), demonstrates that
HER2 signaling selectively increases Tyr phosphorylation
of c-Src at Tyr-215 and Tyr phosphorylation of FAK at
Tyr-861, resulting in the spread of breast cancer cells by
HER2 [10]. Furthermore, co-culturing MCF-7 breast cancer
cells overexpressing HER2 with endothelial cell monolayers
displays that the increased metastatic potential of breast
carcinoma may stem from HER2 induction of endothelial
cell retraction, a process disrupting endothelial integrity
and preceding endothelial cell transmigration in several
tumor metastatic models [11], and the plausible mechanism
involves both down-regulation of vascular endothelial cad-
herin and dissociation of catenins by HER2 [12]. Totally,
tests in both cell-based and animal models conﬁrm a critical
role of HER2 hyperactivation in the development of breast
carcinoma cell invasion and metastasis, consistent with the
observations from clinic studies.
Other possibility that HER2 ampliﬁcation or overexpres-
sion contributes to breast cancer metastasis is up-regulation
of matrix metalloproteinases (MMPs), a family of zinc
and calcium-dependent endoproteinases responsible for the
degradation of extracellular matrix (ECM). A causal link
between MMPs and HER2 has been deciphered by clinico-
pathological evidence. Immunohistochemical and statistical
analysis found that MMP-2 and MMP-9 expressions are
positively related to HER2 overexpression in the stromal
cells of breast carcinoma [13], implicating that MMP-2
or MMP-9 may be a responsive gene of HER2 signaling
in breast cancer metastasis. Several cell-based studies can
provide the molecular basis of the axis of HER2 signaling
to MMP-9 expression in breast carcinoma. Introduction
of HER2 into human MCF-10A breast cancer cells, a
non-tumorigenic epithelial cell line, induced MMP-9 up-
regulation via p38 mitogen-activated protein kinase (p38
kinase) and Akt signaling pathways that further enhanced
the invasive and migratory capacities of MCF-10A cells
[14]. Heregulin-β1( H R G - β1), a natural epidermal growth
factor (EGF)-like ligand for HER3 and HER4 [15] and emits
its signaling by transactivating HER2 [16], is capable of
elevating MMP-9 expression and secretion via activation of
several major HER2-mediated downstream signaling path-
ways, including mitogen-activated protein kinase (MAPK)
cascade, p38 kinase cascade and phospholipase Cγ-protein
kinase C (PLCγ-PKC) pathways [17]. On basis of these
studies, it is suggested that MMP-9 may be a valuable target
of therapeutic intervention in breast cancer patients whose
HER2 are overexpressed.
Pterostilbene (trans-3,5-dimethoxy-4 -hydroxystilbene)
(Figure 1(a)), a dimethyl ether analog of resveratrol, belongs
to the naturally occurring stilbene phytoalexin and can be
isolated from some types of berries [18–20]. Pterostilbene
has been suggested to possess anti-neoplastic activity as
eﬀective as resveratrol due to their closely structural simi-
larity [21–24]. Pterostilbene also acts as an iNOS inhibitor
against aberrant crypt foci formation in the azoxymethane-
induced colon carcinogenesis in rats [25]a n dd o w n -
regulates lipopolysaccharide (LPS)-induced iNOS and COX-
2 expression of murine macrophage [26].
The anti-cancer activities of pterostilbene have, over the
years, attracted the attention of many researchers; however,
the inhibitory eﬀect of pterostilbene on HER2-mediated
breast cancer cell invasion has not yet been investigated.
To this end, we used HRG-β1t ot r a n s a c t i v a t eH E R 2
signaling and investigated whether pterostilbene inhibits
HER2-mediated invasion, metastasis and MMP-9 expression
of breast carcinoma. We also examined the eﬀects of
pterostilbene on several major HER2-mediated downstream
signaling pathways responsible for MMP-9 expression. Then,
we tried to deﬁne the cancer-preventive action of pterostil-
bene in HER2-positive breast carcinoma.
2. Methods
2.1. Materials. Recombinant human heregulin-β1w a sp u r -
chased fromR&DSystems(Minneapolis, MN, USA). Pteros-
tilbene, p38 kinase inhibitor SB203580, MEK inhibitor
PD98059 and PI3K inhibitor LY294002 were obtained
from Sigma (St Louis, MO, USA). RT–PCR reagents
were from Promega (Madison, WI, USA). The antibodies
against β-actin, HER3 and HER2 were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibod-
ies against phospho-p38 (Thr180/Tyr182), p38, phospho-
ERK1/2 (Thr42/Tyr44), ERK1/2, phospho-Akt (Ser473) and
Akt were from Cell Signaling Technology (Beverly, MA,
USA). The anti-phosphotyrosine (PY) antibody (4G10) was
available from Upstate Biotechnology (Charlottesville, VA,
USA).
2.2. Cell Culture. Monolayer cultures of MCF-7, a HER2-
positive human breast carcinoma, were grown in Dulbecco’s
minimal essential medium (DMEM) supplemented with
10% fetal calf serum (Gibco BRL, Grand Island, NY, USA),
100units/ml of penicillin and 100μg/ml of streptomycin,
and kept at 37◦C in a humidiﬁed atmosphere of 5% CO2 in
air.
2.3.Immunoprecipitation. Onehundredmicrolitercelllysate
(containing 500μg total cellular proteins) was ﬁrst precleared
by being incubated with protein A-agarose (10μl, 50%
slurry, Santa Cruz Biotechnology) for 15min. The clariﬁed
supernatants were collected by microfugation, and then
incubatedwithprimaryantibody for2hat4◦C.Thereaction
mixtures were added with 20μl of protein A-agarose to
absorb the immunocomplexes at 4◦C overnight. Immuno-
precipitated proteins were subjected to 8% SDS–PAGE,
and then transferred onto a PVDF membrane (Millipore).
The native- or phospho-form proteins were visualized by
immunoblotting.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: (a) Chemical structures of resveratrol and pterostilbene. (b) Transactivation of HER2 by heterodimerizing HER3 in response to
HRG-β1.HRG-β1-stimulatedcelllysateswereimmunoprecipitatedwithHER2orHER3antibodies,andthenimmunoblottedforantibodies
against phosphotyrosine (PY), HER3 or HER2. HRG: heregulin-β1; IP: immunoprecipitation.
2.4. Western Blotting (Immunoblotting). Western blotting
was performed as previously described [27]. Brieﬂy, total
protein extracts were prepared in a lysis buﬀer (50mM Tris–
HCl, pH 8.0, 5mM EDTA, 150mM NaCl, 0.5% NP-40,
0.5mM phenylmethanesulfonyl ﬂuoride and 0.5mM dithio-
threitol) for 30min at 4◦C. Equal amounts of total cellular
proteins (50μg) were resolved by SDS–PAGE, transferred
onto polyvinylidene diﬂuoride (PVDF) membranes (Immo-
bilon P, Millipore, Bedford, MA, USA) and then probed
with primary antibody, followed by secondary antibody
conjugated with horseradish peroxidase. The immunocom-
plexes were visualized with enhanced chemiluminescence
kits (Amersham, UK).
2.5. In Vitro Invasion Assay. The migratory ability of the
cells was assayed in Transwell upper and lower chambers
(Costar, Cambridge, MT, USA) separated by a polycarbonate
membrane (8-mm pores, 6.5mm diameter). Before invasion
assays, Matrigel matrix (BD Biosciences, Bedford, MA,
USA) was diluted 80 times with serum-free cold DMEM.
Then the polycarbonate ﬁlter was coated with 100μlo f
diluted Matrigel matrix and allowed to dry overnight. For
invasion assays, 2.5 × 104 serum-starved MCF-7 cells seeded
in the upper well of each chamber were treated with a
variety of concentrations of pterostilbene accompanied with
HRG-β1 (20ng/ml) stimulation, and NIH3T3 ﬁbroblast-
conditioned media was placed in the lower compartment of
thechemotaxischamberasasourceofchemoattractants.The
invasionwasallowedtoproceedfor72h,followedbyﬁxation
with 10% formaldehyde for 10min and staining with 0.25%
CoomassieBrilliantBlueG.Thenumberofcellsinvadingthe
lower side of the ﬁlter was counted under microscopy in 10
random selective ﬁelds.
2.6. Wound-Healing Assay. A cell culture wound-healing
assay was performed following well-established methods
[28]. To study the eﬀects of pterostilbene on HRG-β1-
induced cell migration, serum-starved MCF-7 cells were
grown to conﬂuence and a linear wound was created in
the conﬂuent monolayer using a 200μl micropipette tip.
The cells were then washed with PBS to eliminate detached
cells and diluted in serum-free DMEM. Then, various
concentrationsofpterostilbene wereaddedfor30minbefore
HRG-β1 (20ng/ml) treatment. After 24h of incubation, the
wound edge movement was monitored with a microscope.
2.7. Anchorage-Independent Transformation Assay. Anchor-
age-independent transformation assay (soft agar assay) was
performed as previously described [29]. Brieﬂy, single-cell
suspensions of MCF-7 cells were stimulated with 20ng/ml
of HRG-β1 in the presence of diﬀerent concentrations
of pterostilbene, and then mixed with agarose in a ﬁnal
concentration of 0.35%. Aliquots of 1.5ml containing 104
cells with 10% FCS were plated in triplicate in 6-cm culture
dishes over a base layer of 0.7% agarose and allowed to grow.
Coloniesof>60mmwascountedafter14daysofincubation.
2.8. Cell Viability Assay. MCF-7 cells were seeded at a
density of 5 × 103 cells/ml into 96-well plates and grown4 Evidence-Based Complementary and Alternative Medicine
overnight. Then the cells were transferred into serum-
free medium and incubated for an additional 16h. After
serum starvation, the cells were treated with the indicated
concentrations of pterostilbene for 30min prior to stimu-
lation with 20ng/ml of HRG-β1. After 24h of incubation,
the proliferating cell numbers were determined by the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay. Brieﬂy, 20μl of MTT solution (5mg/ml,
Sigma) was added to each well and incubated for 4h at 37◦C.
Then the supernatant was aspirated, and the MTT-formazan
crystalsformedbymetabolicallyviablecellsweredissolvedin
200μlofdimethylsulfoxide(DMSO).Finally,theabsorbance
was monitored by a microplate reader at a wavelength of
570nm.
2.9. Gelatin Zymographic Assay. Cultures deprived of serum
for 24h were treated with the increasing doses of pterostil-
bene (0, 5, 10, 20 or 30μM) for 30min prior to stimulation
with HRG-β1 (20ng/ml). After 24h, conditioned media
were concentrated 50-fold using Centricon spin columns
(Amicon, Beverly, MA, USA), mixed with Laemmli’s sample
buﬀer in the absence of β-mercaptoethanol, and then
subjected to 10% SDS–PAGE with gels containing 0.1%
gelatin (Sigma). After electrophoresis, the gel was washed
twice in a solution containing 2.5% Triton X-100 to remove
SDS and subsequently incubated in 50mM Tris–HCl (pH
7.5) buﬀer containing 10mM calcium chloride and 1mM
zinc chloride with shaking for 24h at 37◦C. The gelatinolytic
activity were visualized after staining the gel with 0.25%
Coomassie blue in 10% acetic acid and 45% methanol and
then destaining in 10% acetic acid and 5% methanol.
2.10. Reverse Transcription Polymerase Chain Reaction. Total
RNA was isolated using TRIzol reagent (Invitrogen) as
recommendedbythemanufacturer’sinstructions.TotalRNA
(5μg) was reverse-transcribed into cDNA, using Moloney
murine leukemia virus (M-MLV) reverse transcriptase and
oligo (dT) 18 primer by incubating the reaction mixture
(25μl) at 40◦C for 90min. Ampliﬁcation of cDNA was
performed by polymerase chain reaction (PCR) in a ﬁnal
volume of 50μl containing 2μl of reverse transcription (RT)
product, dNTPs (each at 200μM), 1× reaction buﬀer, a 1-
μMconcentrationofeachprimer(MMP-9,forward5 -GGA-
GCCGCTCTCCAAGAAGCTT-3 , reverse 5 -CTCCTC-
CCTTTCCTCCAGAACAGAA-3 ; and GAPDH, forward 5 -
TGAAGGTCGGTGTGAACGGATTTGGC-3 , reverse 5 -
CATGTAGGCCATGAGGTCCACCAC-3 ) and 50units/ml
Pro Taq DNA polymerase. After an initial denaturation for
5minat95 ◦C, 30 cycles of ampliﬁcation (95◦C for 30s, 58◦C
for 1min and 72◦C for 1min) were performed, followed
by 72◦C for 10min. A 5-μls a m p l eo fe a c hP C Rp r o d u c t
was electrophoresed on a 2% agarose gel and visualized by
ethidium bromide staining.
2.11. Statistical Analysis. Mean values between the groups
were compared using the Student’s unpaired two-tailed t-
test. All statistical tests were two-sided, and diﬀerences were
considered signiﬁcant when P<. 05.
3. Results
3.1. Facilitation of HER2–HER3 Heterodimer Formation in
Response to HRG-β1 in MCF-7 Cells. A ligand for HER2 has
not yet been found, but it can be transactivated by forming
heterodimer with HER3 in response to HRG-β1 stimulation.
TounderstandwhetherHRG-β1caninduceHER2activation
via heterodimerization with HER3 in human breast cancer
cell line MCF-7, we analyzed the status of tyrosine phos-
phorylation of HER2 and HER3, a characteristic for RTK
activation, in response to HRG-β1 in MCF-7 cells. HER2
or HER3 protein from HRG-β1-stimulated cell lysates was
puriﬁed by immunoprecipitation, and then phosphorylated
proteins were visualized by immunoblotting with anti-
phosphotyrosine (PY) antibody (4G10 monoclonal anti-
body). As shown in Figure 1(b),e i t h e rH E R 2o rH E R 3
tyrosine phosphorylation was markedly increased in HRG-
β1-treated cells compared with that in HRG-β1-untreated
control. Co-immunoprecipitation assay also showed that
HRG-β1 promoted HER2–HER3 heterodimer formation in
MCF-7 cells (Figure 1(b)). These results indicated that we
could use HRG-β1-stimulated MCF-7 cells to mimic cellular
physiology of HER2-overexpressing breast cancer cells.
3.2. Abrogation of HRG-β1-Mediated Cell Invasion by Pteros-
tilbene in a Transwell Assay. HRG-β1w a sr e po rt edt oi n v o l v e
in the regulation of tumorigenesis and metastasis of breast
cancer [30–32]. To assess the eﬀect of pterostilbene on
HRG-β1-modulated invasion, HRG-β1-stimualted MCF-7
cells were allowed to invade through reconstituted basement
membranes (Matrigel) by Transwell assay. Representative
micrographsofTranswellﬁltersareshowninFigure 2.HR G-
β1 dramatically promoted the invasion activity of MCF-7
cells compared with that of the control, while the addition
of pterostilbene to MCF-7 cells led to a dose-dependent
inhibition on HRG-β1-mediated cell invasion. This ﬁnding
revealed that pterostilbene was able to suppress HRG-β1-
associated invasion of breast cancer cells.
3 . 3 .R e s t r i c t i o no nI nV i t r oM i g r a t i o no fH R G - β1-Stimulated
Cells by Pterostilbene. Next, to evaluate the eﬀect of pteros-
tilbene on HRG-β1-induced cell motility, the cell culture
wound-healing assay, an established method to study direc-
tional cell migration in vitro [33], was employed. Incubation
of serum-starved MCF-7 cells with HRG-β1p r o d u c e da
markedcellmigrationinthewoundareaat24hafterwound-
ing;whereaswoundstreatedwithpterostilbeneshoweddose-
related delays in wound healing under the same conditions
(Figure 3). The result indicated that pterostilbene inhibited
HRG-β1-induced motility of breast cancer cells in vitro.
3.4. Retardation of HRG-β1-Mediated Cell Transformation
by Pterostilbene. Anchorage-independent growth is posi-
tively linked to metastatic potential [34]. To investigate
the inhibitory eﬀects of pterostilbene on HRG-β1-induced
tumorigenicity in vitro,H R G - β1-stimulated MCF-7 cells
were seeded on a soft agar, and the transformed coloniesEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀect of pterostilbene on HRG-β1-mediated human breast cancer cell invasion. Invasion of tumor cells was analyzed in Transwell
Boyden chambers with a polycarbonate ﬁlter of 8-μm pore size. Serum-starved MCF-7 cells were seeded in Transwell upper chamber coated
with a 1:80 diluted Matrigel. After 12 h attachment, cells plated in upper chamber were treated with HRG-β1 (20ng/ml) in the presence of
the indicated concentrations of pterostilbene and allowed to invade for 72h. Invading cells on the lower surface of ﬁlter were stained and
quantiﬁed with microscope. For quantiﬁcation, the number of invasive cells were counted in 10 random selective ﬁelds per well and each bar
represents mean ± SE of three independent experiments. ∗∗P<. 01 and ∗∗∗P<. 001 compared with HRG-β1-stimulated group; ###P<. 001
compared with serum-deprived control. PTER represents pterostilbene.
greater than 60μm were counted. After 2 weeks of incu-
bation, HRG-β1 increased about 50% of the transformed
colonies compared with that of the unstimulated control,
and this capacity of soft agar colony formation by HRG-
β1 was markedly inhibited by pterostilbene with a lower
number of colonies formed and a reduced colony size in
a concentration-responsive manner (Figure 4). Notably, the
number of colonies formed at the high doses of pterostilbene
(10–30μM) was much lower than that of the unstim-
ulated control. These results suggested that pterostilbene
strongly inhibited anchorage-independent growth in HRG-
β1-stimulated MCF-7 cells and this eﬀect might, in part, be
due to the cytotoxicity of pterostilbene.
3.5. Viability of HRG-β1-Stimulated MCF-7 Cells in the
Presence of Pterostilbene. The anti-tumorigenic eﬀect of6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of pterostilbene on HRG-β1-modulated wound healing. MCF-7 cells were seeded on 6-well plates, starved, and grown to
conﬂuence. A scrape wound was generated in the cell layer, and the culture was treated with pterostilbene at a concentration of 0, 5, 10 or
20μM for 30min prior to HRG-β1 (20ng/ml) stimulation. Then the cells on the edge of the wound were allowed 24h to migrate across
the wound. All of the results were monitored by microscopy. Relative distance of the wound width was measured and divided by the initial
half-width of the wound. Results are expressed as the mean ± SE of three independent experiments. ∗P<. 05, ∗∗P<. 01 and ∗∗∗P<. 001
versus HRG-β1-stimulated control; ###P<. 001 compared with serum-starved control.
pterostilbene on soft agar assay led us to determine whether
this inhibition by pterostilbene resulted from its cytotoxicity.
Thus, the anti-proliferating activity of pterostilbene on
HRG-β1-stimulated MCF-7 cells was examined by means
of MTT method with the indicated concentrations of
pterostilbene as shown in Figure 5. The result showed
that pterostilbene slightly inhibited HRG-β1-stimulated cell
proliferation, but the inhibitory eﬃcacy of pterostilbene on
cell growth was obviously lower than that on invasion and
motility (Figures 2 and 3(a), resp.), indicating that growth
inhibition is unsuﬃcient to explain the down-regulation of
HRG-β1-induced metastatic spread by pterostilbene.Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀects of pterostilbene on colony formation of HRG-β1-stimulated MCF-7 cells. Serum-starved MCF-7 cells were treated with
diﬀerent concentrations of pterostilbene, together with stimulation by HRG-β1 (20ng/ml), in 0.35% agarose containing 1% FCS over 0.7%
agarose containing 1% FCS.Cellcolonies were counted by light microscopy after a 14-day incubation at 37◦Ci n5 %CO 2. For quantiﬁcation,
colonies greater than 60mm were scored. Statistical analysis was analyzed by t-test. ∗∗P<. 01 and ∗∗∗P<. 001 compared with HRG-β1-
stimulated group; #P<. 05 compared with serum-starved control.
3.6. Suppressive Eﬀects of Pterostilbene on the Activity and
E x p r e s s i o no fM M P - 9I n d u c e db yH R G - β1. MMP-9 plays
important role in the facilitation of tumor invasion and
metastasis, and recent evidence has shown that HRG-
β1 can stimulate MMP-9 secretion and activation via a
transcriptional regulation in human breast cancer cells [17].
Thus, to understand the anti-invasive and anti-metastatic
mechanisms of pterostilbene, the possibility of pterostilbene
aﬀecting the activity and expression of MMP-9 in HRG-β1-
activated MCF-7 cells was assessed by zymographic assay
and western blot analysis, respectively. The result from
zymogram gels indicated that pterostilbene down-regulated
HRG-β1-modulated MMP-9 activation in a dose-related
manner (Figure 6(a)). Subsequently, as shown by western
blotting, pterostilbene blocked the expression of pro-MMP-
9p r o t e i nb yH R G - β1i nM C F - 7c e l l s( Figure 6(b)), and the8 Evidence-Based Complementary and Alternative Medicine
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Figure 5:EﬀectofpterostilbeneonHRG-β1-stimulatedMCF-7cell
viability. Serum-starved MCF-7 cells were pretreated with 0, 5, 10,
20 or 30μM of pterostilbene for 30 min before 20ng/ml of HRG-
β1 was added into the culture medium. After 24h of incubation,
the cell viability was determined by the MTT assay as described in
Section 2, and the results are shown as the cell number relative to
that of the unstimulated cells. Each experiment was independently
performed three times and expressed as the mean ± SE. ∗∗P<. 01
compared with the HRG-β1-treated control; #P<. 05 compared
with serum-starved control.
pattern of protein levels of pro-MMP-9 correlated well with
that of MMP-9 gelatinolytic activity shown in zymographic
assay (Figure 6(a)), indicating that suppression of HRG-β1-
induced MMP-9 gelatinolytic activity by pterostilbene was
due to the blockade of pro-MMP-9 protein production by
HRG-β1.
In order to investigate whether the decreased HRG-β1-
mediated MMP-9 protein level by pterostilbene was due
to the down-regulation of MMP-9 mRNA, RT–PCR was
performed on HRG-β1-stimulated MCF-7 cells in the pres-
ence or absence of pterostilbene. As shown in Figure 6(c),
pterostilbene dose-dependently reduced HRG-β1-induced
MMP-9 mRNA expression of MCF-7 cells, suggesting that
pterostilbene might reduce the HRG-β1-induced MMP-9
expression through transcriptional regulation or modiﬁca-
tion of upstream kinase cascades.
3.7. Selective Inhibition of Pterostilbene on HRG-β1-
Downstream Kinase Signaling Responsible for MMP-9
Induction. The activation of p38- and ERK1/2-MAP kinase
cascade pathways are involved in the transcriptional up-
regulation of MMP-9 by HRG-β1[ 17]. To elucidate whether
pterostilbene down-regulated HRG-β1-related MMP-9
expression by virtue of the modulation of activation of
p38 kinase and ERK1/2, we performed immunoblotting
to detect the eﬀects of pterostilbene on HRG-β1-induced
p38 kinase and ERK1/2 phosphorylation, which have direct
positive correlation with their activation. SB203580 (p38
inhibitor) and PD98059 (MEK inhibitor) were used to
identify the molecular signaling pathways by which HRG-β1
stimulates MMP-9 expression (Figures 7(a) and 7(b),
resp.). Pterostilbene as eﬀective as SB203580 (p38 inhibitor)
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Figure 6: Eﬀects of pterostilbene on HRG-β1-mediated MMP-9
activity and expression in MCF-7 breast cancer cells. (a) Inhibition
ofHRG-β1-mediatedMMP-9gelatinolyticactivitybypterostilbene.
Serum-starved MCF-7 cells were pretreated with 0, 5, 10, 20 or
30μM of pterostilbene for 30min followed by exposure to 20ng/ml
of HRG-β1. After 24h of incubation, the conditioned medium was
collected and subjected to zymography. (b) Inhibition of HRG-β1-
mediated MMP-9 protein expression by pterostilbene. Cells were
pretreated with various concentrations of pterostilbene for 30min
in serum-free media and then stimulated by 20ng/ml of HRG-
β1 for 24h. At the end of incubation, total proteins in cellular
extracts were collected and assayed by western blotting using an
antibody against MMP-9. β-Actin was an internal control for
equivalent protein loading. (c) Dose-related inhibition of HRG-β1-
induced increase in MMP-9 protein level by pterostilbene. Serum-
starved cells were stimulated with HRG-β1( 2 0 n g / m l )f o r2 4 h
after pretreatment of pterostilbene at the indicated concentrations.
Then total RNA was isolated, and RNA expression was analyzed
by RT–PCR as described in Section 2. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA was used as an internal control.
reduced the phosphorylation of p38 kinase (Figure 7(a));
however, pterostilbene had no notable eﬀect of on ERK1/2
phosphorylation (Figure 7(b)). These results suggested
that pterostilbene blocked HRG-β1-mediated MMP-9
up-regulation through inhibiting p38 kinase rather than
ERK1/2 in MCF-7 cells.
3.8. Dose-Related Repression on HRG-β1-Elicited Akt Phos-
phorylation/Activation by Pterostilbene. PI3K-Akt pathway
is thought to be responsible for HRG-β1-associated cell
proliferation. To evaluate whether the growth inhibition
by pterostilbene may come from suppression of PI3K-Akt
pathway, the eﬀect of pterostilbene on HRG-β1-induced Akt
phosphorylation (activation) was determined. Figure 7(c)
displays that pterostilbene caused a dose-dependent decreaseEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: Eﬀects of pterostilbene on the activation of p38 kinase, ERK1/2 and Akt in HRG-β1-stimulated cells. Serum-starved MCF-7
cells were pretreated with a variety of concentrations of pterostilbene, SB203580 (p38 kinase inhibitor, 20μM), or PD98059 (MEK inhibitor,
50μM)for30minandthenstimulatedbyHRG-β1(20ng/ml)for10min.(a)Phosphorylatedp38kinase(p-38),(b)phosphorylatedERK1/2
(p-ERK1/2), (c) phosphorylated Akt (p-Akt) or MMP-9 was determined by western blotting. The native protein or β-actin was used as a
loading control.
in HRG-β1-induced Akt phosphorylation, correlated well
with anti-proliferating eﬀect (Figure 5). Combined with
these ﬁndings, we suggest that the blockage of HRG-β1-
induced proliferation by pterostilbene via an inhibitory
modiﬁcation of Akt may partially contribute to anti-
metastatic and invasive capacity of pterostilbene in MCF-7
breast carcinoma cells.
4. Discussion
Clinically, up-regulation of MMPs is tightly associated with
HER2 overexpression that imparts the aggressive and inva-
sive potential to breast cancer with decreased survival [13].
Transfection of MCF-10A human breast epithelial cells with
HER2 was suﬃcient to induce a more aggressive phenotype
through MMP-9 and MMP-2 induction [14, 35]. These
evidences suggest that HER2-bearing breast cancer cells,
in part, acquire metastatic ability through up-regulation
of MMPs. Thus, suppression of HER2-mediated MMP
expression by chemopreventive agents may be an attractive
strategy to reduce the incidence of malignant breast tumor
development. Herein, the role of pterostilbene against HRG-
β1/HER2-induced MMP-9 expression and invasion of MCF-
7 human breast cancer cells has been ﬁrst investigated.
Our results showed that pterostilbene was able to suppress
HRG-β1-mediated MMP-9 activation and expression with
consequent suppression of cell invasion, migration and
colony formation of MCF-7 cells (Figures 6, 2, 3,a n d4,
resp.).
Analysisofsteady-statelevelsofMMP-9mRNAindicated
that pterostilbene inhibited HRG-β1-driven MMP-9 mRNA
expression (Figure 6(c)). HRG-β1 is known for its ability to
promote aggressive and invasive phenotypes of breast carci-
noma by elevating the expression of MMP-9 via the MAPK
and p38 kinase cascade pathways [17]. Both MAPK and p38
kinase pathways were reported to regulate the expression
of MMP-9 by inducing AP-1-dependent promoter acti-
vation [36, 37]. In the light of these ﬁndings, HRG-β1-
induced MMP-9 expression might be transcriptional. Thus,
we postulated that the action mechanism of pterostilbene
against cell invasion and metastasis of breast carcinoma
might include the regulation or interference with these10 Evidence-Based Complementary and Alternative Medicine
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Figure 8: Schematic models depicting the eﬀects of pterostilbene
onHRG-β1-mediatedaggressivephenotypesofMCF-7cells.PTER:
pterostilbene; HRG-β1: heregulin-β1; PI3K: phosphotidylinositol
3-kinase; PDK: phosphotidylinositol-3,4,5-triphosphate dependent
kinase; p38 kinase, p38 MAP kinase; AP-1: activator protein-1;
ECM: extracellular matrix. The arrow symbol represents direct or
multistep activation; the T-like symbol represents site of inhibition
by pterostilbene.
signalingpathwaysresponsibleforHRG-β1-mediatedMMP-
9 induction. Consistent with our assumption, pterostilbene
has a dose-dependent inhibition on the phosphorylation
of p38 kinase, a hallmark of kinase activation, but not
the phosphorylation of ERK1/2 in HRG-β1-stimulated cells
(Figures 7(a) and 7(b)), indicating that down-regulation of
p38 kinase pathway might be one of the possible reasons
for suppression of HRG-β1-elicted MMP-9 induction and
invasion of breast cancer cells by pterostilbene.
Although anti-metastatic activity of pterostilbene on
HRG-β1-stimulated cells can be explained to stem from its
capacity of down-regulation of MMP-9 induction, dramatic
inhibition of HRG-β1-induced colony formation and migra-
tion beyond the range of MMP-9 reduction was observed
with treatment of pterostilbene at high concentrations
in MCF-7 cells. It is likely that pterostilbene may aﬀect
other causal factors as well as MMP-9 expression that are
responsible for colony formation and wound healing of
MCF-7 cells triggered by HRG-β1. Interestingly, Tang et al.
reported that resveratrol inhibits HRG-β1-mediated MMP-
9 expression and cell invasion in MCF-7 cells [38], and it
is known that resveratrol commits MCF-7 cells to apoptosis
by accumulation oxidative stress and subsequent activation
of diﬀerent classes of MAP kinase pathways [39]. Moreover,
our previous study found that pterostilbene was able to
induce cell cycle arrest and apoptosis of human gastric
carcinoma [40]. It raises the possibility whether pteros-
tilbene acquires the ability to inhibit HRG-β1-associated
cell invasion and cell transformation of breast carcinoma
from its cytotoxicity. Our result indicated that HRG-β1
increased the cell proliferating rate in serum-starved MCF-
7 cells and pterostilbene treatment reduced this elevated
eﬀect in a dose-related manner (Figure 5). Correlation with
this growth inhibition, pterostilbene also dose-dependently
blocked HRG-β1-induced phosphorylation (activation) of
Akt, a prominent regulator for cell survival and transforma-
tion. On the basis of these ﬁndings, we infer that suppression
ofcolonyformationandwoundhealingbypterostilbenemay
partly result from growth inhibition in HRG-β1-stimulated
cells, but the details of how these eﬀects take place remain to
be further elucidated.
To sum up, the data given here provide clear evidence
thatpterostilbeneabolishestheabilityofHRG-β1-stimulated
cells to metastasize and invade from two alternative path-
ways, as illustrated in Figure 8. One model of pterostilbene
against metastasis is that pterostilbene exerts an inhibitory
eﬀect on p38 kinase pathway where it regulates HRG-
β1-driven MMP-9 induction, invasion and migration of
MCF-7 breast cancer cells. The other possible mechanism
is that pterostilbene inhibits the PI3K/Akt pathway that
is required for cell proliferation and transformation in
response to HRG-β1. Under-standing the molecular basis
of anti-tumor activity of pterostilbene, in conjunction with
its low toxicity and non-mutagenic nature, will make it a
potentially chemopreventive and therapeutic agent against
some types of cancers.
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